APIS Assay Technologies

APIS has launched several diagnostic kits for oncology and pharmacogenomics applications. Their breast cancer subtyping kit detects standard and novel biomarkers. The ESR1 qPCR/dPCR kits detect key estrogen receptor mutations relevant to therapy resistance. The PIK3CA qPCR kit identifies common oncogenic mutations. Their DPYD kit supports safer chemotherapy dosing by identifying patients at risk of severe toxicity. Infectious disease kits include those for SARS-CoV‑2 antibodies and tick-borne encephalitis virus. They have an active partnership with Biocartis to commercialize the ESR1 Mutations Kit globally. No clinical trial results as they focus on diagnostics.